Summary by Futu AI
Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of August 7, 2024, at 4:30 P.M. The Form S-3 is a registration form that allows companies to provide updated financial information and securities offerings to potential investors. This effectiveness indicates that Vivos Therapeutics has met the necessary regulatory requirements to move forward with its securities offerings.